The proposed takeover bid for Seer includes additional contingent value rights, signaling a significant shift for the firm as Farokhzad seeks to take the company private. Elsewhere in the sector, Orthofix Medical saw its stock rise 7.9% to $10.72 following a decision by the Centers for Medicare & Medicaid Services to restore previous reimbursement rates. This reversal effectively undoes recent financial headwinds for the medical device provider.

Conversely, Halozyme Therapeutics faced downward pressure after announcing the departure of its chief operating officer. The news prompted a 3.1% decline in the company's stock, which settled at $77.00. These disparate movements underscore how specific corporate governance changes and regulatory shifts continue to dictate immediate market valuations for healthcare equities.